BTG plc (BTG) Rating Reiterated by Numis Securities Ltd
BTG plc (LON:BTG)‘s stock had its “buy” rating restated by equities researchers at Numis Securities Ltd in a research report issued on Wednesday. They presently have a GBX 900 ($11.96) target price on the stock. Numis Securities Ltd’s target price suggests a potential upside of 23.80% from the stock’s current price.
Several other brokerages have also weighed in on BTG. Deutsche Bank AG reissued a “buy” rating and issued a GBX 775 ($10.30) price objective on shares of BTG plc in a report on Friday, October 13th. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Peel Hunt reissued a “hold” rating and issued a GBX 680 ($9.04) price objective on shares of BTG plc in a report on Wednesday, September 20th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 800 ($10.63) price objective on shares of BTG plc in a report on Wednesday, August 30th. Finally, Shore Capital reissued a “not rated” rating on shares of BTG plc in a report on Thursday, July 13th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. BTG plc has a consensus rating of “Buy” and an average target price of GBX 780.33 ($10.37).
BTG plc (BTG) opened at 749.17 on Wednesday. The firm’s market capitalization is GBX 2.89 billion. The firm has a 50 day moving average of GBX 688.81 and a 200 day moving average of GBX 669.72. BTG plc has a 12-month low of GBX 528.36 and a 12-month high of GBX 752.50.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/btg-plc-btg-rating-reiterated-by-numis-securities-ltd/1638241.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.